Stockscreener 앱 받기
4.33
2.61%
0.11
전일 마감가:
$4.22
열려 있는:
$4.29
하루 거래량:
100.77K
Relative Volume:
0.12
시가총액:
$152.93M
수익:
-
순이익/손실:
$-144.01M
주가수익비율:
-1.0798
EPS:
-4.01
순현금흐름:
$-113.02M
1주 성능:
-3.35%
1개월 성능:
+11.60%
6개월 성능:
-18.61%
1년 성능:
-75.59%
1일 변동 폭
$4.25
$4.38
1주일 범위
$4.13
$4.59
52주 변동 폭
$3.61
$20.21
바이오미아 퓨전 Stock (BMEA) Company Profile
명칭
Biomea Fusion Inc
전화
(650) 980-9099
주소
900 MIDDLEFIELD ROAD, REDWOOD CITY
BMEA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMEA
Biomea Fusion Inc
|
4.33 | 152.93M | 0 | -144.01M | -113.02M | -4.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.80 | 113.70B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.29 | 75.52B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
663.27 | 39.78B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.25 | 35.34B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
121.37 | 29.05B | 3.30B | -501.07M | 1.03B | -2.1146 |
바이오미아 퓨전 Stock (BMEA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-09 | 개시 | Edward Jones | Buy |
| 2024-09-27 | 업그레이드 | Rodman & Renshaw | Neutral → Buy |
| 2024-09-27 | 업그레이드 | Truist | Hold → Buy |
| 2024-08-29 | 개시 | CapitalOne | Overweight |
| 2024-06-11 | 다운그레이드 | Truist | Buy → Hold |
| 2024-06-07 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-04-02 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-02-06 | 개시 | Truist | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Outperform |
| 2023-06-26 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-05-12 | 개시 | Barclays | Overweight |
| 2023-03-29 | 재확인 | Oppenheimer | Outperform |
| 2023-03-28 | 재확인 | H.C. Wainwright | Buy |
| 2023-02-24 | 개시 | Citigroup | Buy |
| 2022-06-02 | 재개 | H.C. Wainwright | Buy |
| 2022-01-12 | 개시 | H.C. Wainwright | Buy |
| 2021-12-17 | 개시 | Oppenheimer | Outperform |
| 2021-05-11 | 개시 | JP Morgan | Overweight |
| 2021-05-11 | 개시 | Jefferies | Buy |
| 2021-05-11 | 개시 | Piper Sandler | Overweight |
모두보기
바이오미아 퓨전 주식(BMEA)의 최신 뉴스
Barclays PLC Purchases 24,162 Shares of Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
HC Wainwright Reaffirms Buy Rating for Biomea Fusion (NASDAQ:BMEA) - MarketBeat
Biomea Fusion to Become a Diabetes & Obesity Medicines Company - GlobeNewswire
Biomea Fusion Pivots to Diabetes Focus After Breakthrough Drug Shows 1.5% HbA1c Reduction - StockTitan
Biomea Fusion (NASDAQ:BMEA) Earns “Buy” Rating from D. Boral Capital - Defense World
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Average Rating of “Buy” from Analysts - Defense World
Biomea Fusion, Inc. (NASDAQ:BMEA) Given Average Rating of "Buy" by Analysts - MarketBeat
Biomea Fusion's (BMEA) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
Recent uptick might appease Biomea Fusion, Inc. (NASDAQ:BMEA) institutional owners after losing 75% over the past year - Simply Wall St
BMEABiomea Fusion, Inc. Latest Stock News & Market Updates - StockTitan
Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study - GlobeNewswire
Biomea's Icovamenib Boosts Semaglutide Effects: 11.5% Extra Weight Loss, 43% More Muscle Mass - StockTitan
10 Best Diabetes Stocks To Buy Under $10 - Insider Monkey
Here’s Why Biomea Fusion, Inc. (NASDAQ:BMEA) Is Among the Best Diabetes Stocks to Buy Under $10 - Insider Monkey
Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Biomea Fusion CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Geode Capital Management LLC Raises Holdings in Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
Barclays PLC Increases Stock Position in Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
Biomea Fusion, Inc. (NASDAQ:BMEA) Short Interest Update - Defense World
State Street Corp Decreases Stock Position in Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
Biomea Fusion (BMEA) – Analysts’ Weekly Ratings Changes - Defense World
Biomea Fusion Advances Diabetes Treatment with Positive Study Results - TipRanks
Biomea Fusion's SWOT analysis: clinical hold casts shadow on diabetes drug stock - Investing.com
Biomea Fusion shares hold with Buy rating after trial success By Investing.com - Investing.com Australia
Biomea Fusion shares hold with Buy rating after trial success - Investing.com
Biomea stock sinks 16% after Phase 2 data release - MSN
Biomea Fusion's (BMEA) Buy Rating Reiterated at D. Boral Capital - MarketBeat
Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes - The Manila Times
Biomea Fusion Announces Positive Topline Results from - GlobeNewswire
Biomea Fusion's Diabetes Drug Shows Breakthrough Results in Phase II Trial, Achieves Key HbA1c Reductions - StockTitan
The Manufacturers Life Insurance Company Takes Position in Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
Analysts Set Biomea Fusion, Inc. (NASDAQ:BMEA) Target Price at $39.36 - MarketBeat
Biomea Fusion, Inc. (NASDAQ:BMEA) Given Consensus Rating of “Buy” by Analysts - Defense World
Biomea Fusion (NASDAQ:BMEA) Receives Buy Rating from HC Wainwright - Defense World
Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D) - The Manila Times
Biomea Fusion to Host Conference Call to Announce Topline - GlobeNewswire
Biomea Fusion to Unveil Key Phase II Diabetes Trial Results: COVALENT-111 Data Release Set for December - StockTitan
Biomea Fusion (NASDAQ:BMEA) Receives "Buy" Rating from HC Wainwright - MarketBeat
Biomea Fusion's SWOT analysis: stock faces challenges amid clinical hold By Investing.com - Investing.com South Africa
Charles Schwab Investment Management Inc. Grows Position in Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
Biomea Fusion's SWOT analysis: stock faces challenges amid clinical hold - Investing.com
Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) - The Manila Times
Biomea Fusion Announces Oral and Poster Presentations of - GlobeNewswire
Biomea Fusion Unveils Breakthrough Preclinical Data: Menin Inhibitor Boosts GLP-1 Therapy Effectiveness - StockTitan
HC Wainwright Reaffirms “Buy” Rating for Biomea Fusion (NASDAQ:BMEA) - Defense World
HC Wainwright Reaffirms "Buy" Rating for Biomea Fusion (NASDAQ:BMEA) - MarketBeat
D. Boral Capital Reiterates "Buy" Rating for Biomea Fusion (NASDAQ:BMEA) - MarketBeat
Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia - The Manila Times
바이오미아 퓨전 (BMEA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.69%
4.93%
자본화:
|
볼륨(24시간):